A Phase Ib/II Study of WNT974 + Encorafenib + Cetuximab in Patients With BRAFV600E-Mutant KRAS Wild-Type Metastatic Colorectal Cancer

Josep Tabernero*, Eric Van Cutsem, Elena Garralda, David Tai, Filippo De Braud, Ravit Geva, Mark T.J. van Bussel, Katia Fiorella Dotti, Elena Elez, María J. De Miguel, Kevin Litwiler, Danielle Murphy, Michelle Edwards, Van Karlyle Morris

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

22 Scopus citations

Fingerprint

Dive into the research topics of 'A Phase Ib/II Study of WNT974 + Encorafenib + Cetuximab in Patients With BRAFV600E-Mutant KRAS Wild-Type Metastatic Colorectal Cancer'. Together they form a unique fingerprint.

Keyphrases

Pharmacology, Toxicology and Pharmaceutical Science